Mega Lifesciences Performance degli utili passati
Criteri Il passato verificati 4/6
Mega Lifesciences ha registrato una crescita degli utili a un tasso medio annuo di 1%, mentre il settore Pharmaceuticals ha registrato utili in crescita a un tasso medio annuo di 8.1%. I ricavi sono stati in crescita a un tasso medio annuo di 0.9%. Il ritorno sul capitale proprio di Mega Lifesciences è 19.7% e ha margini netti di 14.4%.
Informazioni chiave
1.00%
Tasso di crescita degli utili
1.00%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 12.39% |
| Tasso di crescita dei ricavi | 0.86% |
| Rendimento del capitale proprio | 19.67% |
| Margine netto | 14.35% |
| Prossimo aggiornamento sugli utili | 13 Aug 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Jun 24
MEGA: Higher Margins And Lower Growth Will Likely Keep Shares Fairly Valued
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB35.0, explaining that slightly softer revenue growth assumptions are offset by a higher profit margin outlook and a marginally lower future P/E multiple in their updated price target work. What’s in the News for Mega Lifesciences No recent company specific news items for Mega Lifesciences were identified in the provided sources.
Aggiornamento narrativa • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.Aggiornamento narrativa • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Aggiornamento narrativa • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).Aggiornamento narrativa • Apr 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).Aggiornamento narrativa • Mar 23
MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
Aggiornamento narrativa • Mar 09
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.Aggiornamento narrativa • Feb 23
MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.Aggiornamento narrativa • Feb 09
MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.Aggiornamento narrativa • Jan 25
MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.Aggiornamento narrativa • Jan 10
MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.Aggiornamento narrativa • Dec 24
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.Aggiornamento narrativa • Dec 09
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.Aggiornamento narrativa • Nov 25
MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.Nuova narrativa • Jun 01
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Mega Lifesciences guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 14,399 | 2,067 | 4,467 | 0 |
| 31 Dec 25 | 14,195 | 1,912 | 4,481 | 0 |
| 30 Sep 25 | 14,191 | 1,974 | 4,386 | 0 |
| 30 Jun 25 | 14,312 | 1,863 | 4,383 | 0 |
| 31 Mar 25 | 14,859 | 1,985 | 4,382 | 0 |
| 31 Dec 24 | 15,385 | 2,012 | 4,385 | 0 |
| 30 Sep 24 | 15,882 | 1,846 | 4,410 | 0 |
| 30 Jun 24 | 15,685 | 1,999 | 4,331 | 0 |
| 31 Mar 24 | 15,718 | 2,017 | 4,230 | 0 |
| 31 Dec 23 | 15,716 | 1,993 | 4,191 | 0 |
| 30 Sep 23 | 15,442 | 1,919 | 4,278 | 0 |
| 30 Jun 23 | 15,693 | 2,042 | 4,352 | 0 |
| 31 Mar 23 | 15,634 | 2,081 | 4,398 | 0 |
| 31 Dec 22 | 15,727 | 2,242 | 4,359 | 0 |
| 30 Sep 22 | 15,116 | 2,338 | 4,068 | 0 |
| 30 Jun 22 | 15,061 | 2,292 | 4,054 | 0 |
| 31 Mar 22 | 14,724 | 2,227 | 3,924 | 0 |
| 31 Dec 21 | 14,172 | 1,947 | 3,769 | 0 |
| 30 Sep 21 | 14,395 | 1,878 | 3,767 | 0 |
| 30 Jun 21 | 13,775 | 1,607 | 3,538 | 0 |
| 31 Mar 21 | 12,809 | 1,406 | 3,331 | 0 |
| 31 Dec 20 | 12,613 | 1,393 | 3,288 | 0 |
| 30 Sep 20 | 12,168 | 1,348 | 3,169 | 0 |
| 30 Jun 20 | 11,642 | 1,288 | 3,137 | 0 |
| 31 Mar 20 | 11,655 | 1,205 | 3,195 | 0 |
| 31 Dec 19 | 11,164 | 1,139 | 3,176 | 0 |
| 30 Sep 19 | 10,950 | 1,163 | 3,198 | 0 |
| 30 Jun 19 | 10,712 | 1,136 | 3,153 | 0 |
| 31 Mar 19 | 10,569 | 1,203 | 3,113 | 0 |
| 31 Dec 18 | 10,284 | 1,206 | 3,052 | 0 |
| 30 Sep 18 | 10,147 | 1,183 | 3,041 | 0 |
| 30 Jun 18 | 9,937 | 1,175 | 3,010 | 0 |
| 31 Mar 18 | 9,829 | 1,178 | 2,988 | 0 |
| 31 Dec 17 | 9,624 | 1,113 | 2,965 | 0 |
| 30 Sep 17 | 9,514 | 1,023 | 2,928 | 0 |
| 30 Jun 17 | 9,282 | 945 | 2,869 | 0 |
| 31 Mar 17 | 8,968 | 873 | 2,766 | 0 |
| 31 Dec 16 | 8,828 | 795 | 2,674 | 0 |
| 30 Sep 16 | 8,514 | 771 | 2,603 | 0 |
| 30 Jun 16 | 8,226 | 756 | 2,658 | 0 |
| 31 Mar 16 | 8,115 | 703 | 2,714 | 0 |
| 31 Dec 15 | 7,966 | 696 | 2,718 | 0 |
| 30 Sep 15 | 7,775 | 675 | 2,668 | 0 |
Guadagni di qualità: MEGA ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di MEGA (14.4%) MEGA sono più alti rispetto allo scorso anno (13.4%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di MEGA sono cresciuti del 1% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di MEGA nell'ultimo anno ( 4.1% ) supera la media quinquennale ( 1% all'anno).
Guadagni vs Settore: La crescita degli utili MEGA nell'ultimo anno ( 4.1% ) non ha superato quella del settore Pharmaceuticals 8.7%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 19.7% ) di MEGA è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/16 01:03 |
| Prezzo dell'azione a fine giornata | 2026/07/16 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Mega Lifesciences Public Company Limited è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |